DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES 120 :
Total Turn.

GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease

2024-06-13 11:17:00

Ochre and GSK will create a foundational liver biology dataset that could have the potential to further improve translation of novel therapies for liver diseases

OXFORD, England--()--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership will provide GSK with access to Ochre Bio’s computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data.

The collaboration will enable Ochre Bio and GSK to deepen the understanding of liver biology, aligned with GSK’s disease area focus in hepatology, with the aim to further prioritise and accelerate development of medicines to address liver disease. The data will be used by both Ochre Bio and GSK to build better AI models, allowing for fewer, but more precise experiments to aid in target choice.

Jack O’Meara, Co-founder and CEO at Ochre Bio, said:

"Data innovation is as important as algorithmic innovation when investing in ML workflows. Both Ochre Bio and GSK share a commitment to providing liver disease patients with more effective medicines, and believe in a data-driven approach to improve therapeutic discovery. These large-scale, causal human datasets will be foundational for our respective liver R&D pipelines.”

Kim Branson, SVP, Global Head of AI and Machine Learning at GSK, said:

“In addition to our programs in MASH to hepatitis B, we are committed to addressing unmet need in liver disease by generating unique data in human derived systems. Ochre Bio’s platform will provide GSK with foundational data sets to create AI models allowing us to better understand liver function and disease for the development of novel medicines.”

This licence agreement includes data to be generated from single-cell sequencing to study cell populations in perfused human livers, as well as data generated from large-scale gene perturbation in human liver cells.

The deal has a total value of up to $37.5m for both co-exclusive and non-exclusive data licences.

About GSK:

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

About Ochre Bio:

Ochre Bio is a biotechnology company developing novel RNA medicines for under-treated chronic liver diseases. Its proprietary discovery platform combines machine learning and big human datasets, with in-house RNA chemistry, and testing in live human donor livers. Ochre Bio is headquartered in Oxford, UK, and has research labs in New York and Taipei.

To learn more visit: www.ochre-bio.com


Ochre Bio contact: laurenglaser@ochre-bio.com


Interfax Business Wire

People, Passion, Planet: Mary Kay Releases 2024 Sustainability Report
DCO Calls for Urgent Discussions with Member States, Digital Experts to Address Recent Global IT Outage’s Implications
LambdaTest Integrates with Netlify to Enhance Developer Workflows
Laserfiche Global Headquarters Achieves LEED Silver Certification
CSC and Palo Alto Networks Join Forces to Fortify Domain Security for Cortex XSOAR, XSIAM, and XPANSE Users and CSC Domain Registrar Clients
SLB to Accelerate Co-Development of AI-Driven Digital Platform for Aker BP
AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
NIPPON KINZOKU’s Cold Profile Rolled Products Are Named "Fine Profile” to Strengthen Sales Expansion
Andersen Global Broadens Footprint in Czech Republic
Lifezone Metals Produces First-Ever Nickel, Copper and Cobalt from Kabanga Nickel Project
Mavenir Moves in on Market Leader Status in New Omdia Core Vendors Report
Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company
Corpay Cross-Border Named the Official B2B FX Partner for AEG Presents UK in Europe
COOLMAX® EcoMade Fiber Makes Summer Games Debut in Paris
Faraday Adds Video Interface IP to Support All Advanced Planar Nodes on UMC Platform
Corona Cero Brings Same Seats as from Olympic Games Venues to Iconic Sunset Destinations Around the World
Join China Hi-Tech Fair 2024, Where Innovation Meets Global Opportunity
Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution
MSCI Strengthens Private Markets Leadership With Launch of 130 Indexes
Back to Top